ASPI May 2021 Zoom Meeting
Active Surveillance Patients International held a webinar on micro-ultrasound, a hot new imaging technique that helps detect prostate cancers that mpMRI can miss.
ASPI April 2021 Zoom Meeting Part 1 - Speakers
Transperineal (TP) biopsies are emerging as the biggest trend in the care of men on AS for prostate cancer since the mpMRI and genomic testing. The European Urological Association in January 2021 recommended TP as the first choice for biopsies. The American Urological Association will be debating this technology change at its annual meeting in the fall.
A.S.P.I. has assembled an expert panel to discuss why this change is being made, the potential to eliminate sepsis, impact on stewardship of antibiotics, and the differences between transrectal and transperineal biopsies. The discussion will be followed by a question-and-answer period.
ASPI April 2021 Zoom Meeting Part 2 - Q & A
Continuation of the Transperineal Biopsy meeting Part 2 – the Q & A session.
ASPI March 2021 Zoom Meeting
We received such positive feedback from our first town hall that we have decided to hold another. David Keller will share his challenges with a biopsy. His story reinforces why ASPI continue its quest for safer biopsies. Joe Gallo will share his story of various genomic tests. Dale Bryant will discuss being on A.S. then opting for treatment.
ASPI Feb 2021 Zoom Meeting
Dr. Chris Bangma, Chairman of Urology at Erasmus University and Academic Hospital in Rotterdam, The Netherlands, will be the inaugural speaker for Active Surveillance Patients International. Among other topics, he will cover the role of PSA testing in Europe, the role of biopsies and mpMRI scanning, genomics, how AS was developed in Europe, how AS works within the Dutch healthcare system, and what the future holds in terms of liquid biopsy and artificial intelligence.
ASPI Jan 2021 Zoom Meeting
Active Surveillance Patients International is pleased to announce the launching of its first international webinar. Towards that end we will be having a panel discussion representing patients from 4 countries. Each will speak briefly and then attendees ask questions.